PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage…
…
Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners,…
…
Image source: The Motley Fool.DateApr. 30, 2026, 4:30 p.m. ETCall participantsChief Executive Officer — Michael J. FarrellChief Financial Officer —…
Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.…
Here are the stocks making headlines in midday trading.…
(Kurs aktualisiert)
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat dank der ungebrochen…
Eli Lilly liefert ein Quartal zum Staunen: Umsatz +56 % auf 19,8 Mrd. USD, EPS bei 8,55 USD weit über…
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.…
…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat dank der ungebrochen hohen Nachfrage nach seinen Gewichtssenkern…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hat dank der ungebrochen hohen Nachfrage nach seinen Gewichtssenkern…
Eli Lillys weight loss pill launch has been closely watched after the successful start of Novo Nordisks Wegovy pill.…
These are the stocks posting the largest moves in the premarket.…
Eli Lilly and Co (NYSE:LLY) reported stronger-than-expected first-quarter 2026 results on April 30, driven by surging demand for its diabetes…
Eli Lilly raised its annual profit forecast and posted better-than-expected first quarter on Thursday, on steady demand for its ?weight-loss…
Eli Lilly raises annual profit forecast on sustained weight-loss drug demand…
Hims & Hers navigates a pivotal moment: a new Eli Lilly distribution deal lifts analyst targets, whi…
Der US-Pharmagigant Eli Lilly (LLY) schlägt erneut kräftig auf dem Übernahmemarkt zu und untermauert gleichzeitig mit herausragenden Studiendaten seine Vormachtstellung.…
Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and…
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3…
Eli Lilly is a giant in the weight-loss drug realm, and its aiming to grow more.…
Hims & Hers Health (HIMS) is back in focus after fresh analyst coverage spotlighted its Novo Nordisk partnership and broader…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription numbers for…
…
These are the stocks posting the largest moves in midday trading.…
These are the stocks posting the largest moves in midday trading.…
In recent days, Hims & Hers Health expanded its platform so clinicians can prescribe Eli Lilly GLP?1 weight loss treatments,…
Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the days top trending stock…
Eli Lillys newly launched oral weight loss drug was prescribed 3,707 times in the U.S. in the second week after…
Eli Lilly stock slips despite steady GLP-1 script growth…
Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…
The stock of Hims Hers Health ($HIMS) was up as much as 7% after the company announced that it…
On April 23, 2026, Hims & Hers announced that it has begun providing access to Eli Lillys GLP-1 weight-loss products…
Hims Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though…
Earlier this week, Hims & Hers Health said clinicians on its platform can now prescribe Eli Lilly GLP-1 weight loss…
Hims & Hers (HIMS) stock rose 7% after expanding its Eli Lilly deal, adding Zepbound prescriptions to its GLP-1 platform…
Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…
Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…
Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…
Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare…
Hims providers can now send prescriptions to Eli Lilly’s direct-to-consumer pharmacy....…
Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…
?Hims & Hers CEO Andrew Dudum noted that, like Netflix gave users the choice of what they wanted most, Hims…
Hims & Hers Health stock jumped 7% after expanding its platform to include Eli Lillys GLP-1 weight loss medications. Heres…
Hims & Hers stock surges 7% on Eli Lilly partnership expansion…
Eli Lilly and Co (NYSE:LLY)’s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building,…